At a glance
ClinicalIndex Comparison RecordN/ACompleted· 56 enrolled
Drug / intervention
Acyclovir 200 MG +3 moredrug
Likely dose
Acyclovir 200 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic Properties of Acyclovir
In Brief
A clinical study evaluating Acyclovir 200 MG, Acyclovir 400 MG, and 2 other interventions for Drug Use. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The objective of this present study was to asses the pharmacokinetic properties of acyclovir tablet from new product formulation (PT. Kimia Farma (Persero) Tbk) to its innovator product, Zovirax® tablet (Glaxo Wellcome S.A., Aranda, Spain)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Use
CountriesIndonesia
CollaboratorsPT Pharma Metric Labs
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartFeb 2020
Primary CompletionApr 2020
Study CompletionApr 2020
First PostedAug 2021
TodayJul 2026
First PostedAug 3, 2021
Enrollment StartFeb 21, 2020
Primary CompletionApr 20, 2020
Study CompletionApr 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.9 years ago
Interventions
Acyclovir 200 MGdrug
Administered with 240 mL of water
Acyclovir 400 MGdrug
Administered with 240 mL of water
Zovirax 200 MG Tabletdrug
Administered with 240 mL of water
Zovirax 400 MG Tabletdrug
Administered with 240 mL of water